Evaxion Biotech earnings date
Want to see EVAX full AI Analyst Report?
Evaxion Biotech (EVAX) Q3 2026 Earnings Report
EVAX Q3 2026 EPS Results
- Actual EPS
- -$0.01
- Consensus EPS
- -$0.01
- Beat/Miss
- Met expectations
- One Year Ago EPS
- $0.01
EVAX Q3 2026 Revenue Results
- Actual Revenue
- $0
- Expected Revenue
- $0
- Beat/Miss
- Met expectations
- YoY Revenue Growth
- -100.00%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/19/2026
- Time
- Before Open
- Conference Call
- Thursday, November 19, 2026
Evaxion Biotech's next earnings date is estimated for March 4, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call was predominantly positive, supported by strong EVX-01 clinical and immunogenicity data, 89% target precision, oncology pipeline advancement, business development activity, platform recognition, and an extended cash runway toward the end of 2027. The company also acknowledged challenges including a quarterly net loss with no recognized revenue, the pending EVX-04 CTA, the lack of clinical validation for the off-the-shelf approach, incomplete response-correlation data, and early-stage autoimmune programs.
Evaxion said it is refocusing all of its own resources on oncology, advancing EVX-04 in AML and EVX-05 in GBM toward clinical development, broadening EVX-01 beyond advanced melanoma most likely through partnership, and continuing to identify new antigens and indications; the EVX-04 clinical trial application is on track to be filed by the end of the year, with submission expected in the second half of this year, and further patient-population and trial-design details most likely available at that time. The company remains on track for the full year to deliver according to its financial plan and still expects an unchanged yearly cash burn rate of approximately $14 million, with cash runway extended towards the end of 2027; it plans to complete autoimmune concept-validation work for potential partnering, while infectious-disease programs will be pursued with partners only where the partner comes forward.
- Strategic Refocus on OncologyEvaxion is refocusing all of its own resources on applying the AI-Immunology platform to oncology, citing validation and significant opportunity in personalized and off-the-shelf cancer vaccines.
- EVX-01 Phase II Clinical ResultsIn advanced melanoma, EVX-01 produced a 75% objective response rate and a 25% complete response rate at two years. Seven of 13 patients with stable disease or a partial response after 12 weeks of anti-PD-1 therapy improved their response after EVX-01 administration, corresponding to 54%.
- Durable EVX-01 Responses and SafetyIn the one-year extension, clinical responses in all six patients receiving EVX-01 monotherapy lasted until the end of the trial. EVX-01-related adverse events were limited to Grade 1 and Grade 2.
- High AI-Immunology Target PrecisionThe EVX-01 Phase II study demonstrated 89% precision in predicting immunogenic neoantigens, described by the company as a record-high vaccine target precision rate.
- Sustained and Broad Immune ResponsesEVX-01 induced potent vaccine-specific T-cell responses that were sustained throughout the three-year period, including in the absence of anti-PD-1 therapy after the first two years. Eighty-six percent of assessed neoantigen responses were de novo, and CD4+ responses were demonstrated in all evaluated patients while CD8+ responses were detected in nine of 15 patients.
- Correlation Between AI Predictions and Immune ResponseThe company reported a positive correlation between the AI prediction score for individual neoantigens and the magnitude of the observed immune response, with higher prediction scores associated with stronger immune responses.
- Broad Cancer Vaccine Platform OpportunityAI-Immunology is being applied across neoantigens, endogenous retroviral elements, and additional dark genome antigens in development. The platform supports personalized vaccines such as EVX-01 and off-the-shelf vaccines such as EVX-04 for acute myeloid leukemia and EVX-05 for glioblastoma, with potential applications discussed across head and neck, lung, ovarian, bladder, colon, esophageal, testicular, and stomach cancers.
- EVX-04 Progress Toward Clinical DevelopmentFor EVX-04, AI-Immunology evaluated 5 million ERV antigen fragments and corresponding MHC ligands and selected 16 optimal antigen fragment sets. Multiple vaccine candidates were designed and tested, the lead candidate is moving into GMP manufacturing, and final preclinical testing and validation are progressing.
- Advancement of Oncology PipelineEvaxion plans to take EVX-04 in AML and EVX-05 in GBM into the clinic, with EVX-05 being developed in collaboration with Duke University. The company also plans to broaden EVX-01 beyond advanced melanoma, most likely through a partnership, and continue identifying antigens and indications through deeper dark genome analysis.
- Business Development MomentumThe company reported multiple parallel business development conversations involving EVX-01, the future off-the-shelf potential of EVX-04 and EVX-05, and other cancer indications. Partners are evaluating the platform's turnaround time, immune response depth, antigen quality, scoring, delivery modality, and potential expansion into additional indications.
- Recognition for AI-ImmunologyAI-Immunology won the Best Digital Health Solution prize at the International Prix Galien Awards.
- Financial Runway ExtendedEvaxion extended its cash runway toward the end of 2027, compared with prior communications indicating runway into the second half of 2027. The extension was supported primarily by use of the ATM program and disciplined resource allocation.
- Cost Discipline and Financial PlanThe company remains on track for the full year to deliver according to its financial plan and continues to expect an unchanged annual cash burn rate of approximately $14 million. Operating costs were reduced compared with the prior year in R&D, due to fewer headcounts, and in G&A, due to lower capital market costs, while more resources were allocated to business development.
- Progress on 2026 MilestonesEvaxion stated that it has achieved all of its 2026 milestones except for filing the EVX-04 clinical trial application, which is on track to be filed by the end of the year. Target validation data for EVX-04 is expected to be presented at ASH in December, with additional patient population and trial design details potentially available around the CTA filing.
- Continued Infectious Disease and Autoimmune Partnering ActivitiesThe company continues to seek partnerships for EVX-B1 in Staph aureus, EVX-B2 in gonorrhea, EVX-B4 in Group A Streptococcus, and EVX-V1 in CMV. EVX-B3 remains out-licensed to MSD and moving forward, while EVX-B2 continues in collaboration with Afrigen. Evaxion also completed initial work on EVX-B4, started autoimmune concept testing, and plans to complete early validation of tolerogenic vaccine and autoantibody binder concepts for potential partnering.
- Potential for Faster Personalized Vaccine TurnaroundThe current patient-to-vaccine process takes approximately seven weeks from biopsy to administration. Management stated that the decentralized supply chain, multiple CDMOs, and global shipping create opportunities to significantly reduce the turnaround time.
- Additional Potential Financing From WarrantsThe European Investment Bank may receive authorization to exercise warrants that could provide Evaxion with up to another $1.5 million if exercised. The company also noted that it previously recorded a $4.1 million debt cancellation in exchange for those warrants.
EVAX Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 04, 2027 | 2026 (Q4) | -0.01- | -0.02 | ― | ― |
| Nov 19, 2026 | 2026 (Q3) | -0.01-0.01 | 0.01 | -200.00% (-0.02) | |
| Aug 20, 2026 | 2026 (Q2) | -0.01-0.01 | -0.02 | 50.00% (+0.01) | |
| May 07, 2026 | 2026 (Q1) | -0.01-0.01 | -0.01 | 0.00% (+0.00) | |
| Mar 05, 2026 | 2025 (Q4) | -0.24-0.02 | -0.07 | 71.43% (+0.05) | |
| Nov 06, 2025 | 2025 (Q3) | -0.010.01 | -0.2 | 105.00% (+0.21) | |
| Aug 14, 2025 | 2025 (Q2) | -0.58-0.02 | -0.6 | 96.67% (+0.58) | |
| May 27, 2025 | 2025 (Q1) | ―- | 0.15 | ― | |
| Apr 01, 2025 | 2024 (Q4) | -0.70-0.01 | 0.15 | -106.67% (-0.16) | |
| Oct 31, 2024 | 2024 (Q3) | -1.57-0.20 | -10.5 | 98.10% (+10.30) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


